Anvisa approves another medicinal product based on Cannabis
The National Health Surveillance Agency (Anvisa) published this Wednesday (1) the health authorization of another product based on Cannabis . It is an oral solution containing 23.75 milligrams per milliliter (mg/mL) of cannabidiol (CBD), with up to 0.2% of tetrahydrocannabidiol (THC).
According to Anvisa, the product, manufactured in Colombia, should be sold in pharmacies and drugstores in Brazil through a type B prescription (blue). This is the eighth cannabis-based product approved by the agency.
Prescription
Also according to the agency, cannabidiol can be prescribed when other therapeutic options available on the Brazilian market are exhausted. The indication and form of use are the responsibility of the physician, and the patient must be instructed in detail about its use.
Text translated using artificial intelligence.
